Integrated Evidence Planning: How Digital Transformation Is Changing How Biopharma Builds Its Eviden

For most of the past two decades, evidence generation in biopharma happened in silos. Clinical development built its evidence case for regulators. Health economics and outcomes research (HEOR) built a separate case for payers. Medical affairs built yet another for physicians and formulary committees. Integrated evidence planning emerged as a response to that fragmentation — a single, cross-functional strategy that maps out what evidence is needed, by whom, and when, across the entire product lifecycle. As life sciences digital transformation accelerates, the way companies actually build and maintain these plans is changing just as much as the concept itself.

What Integrated Evidence Planning Actually Means

An integrated evidence plan (IEP) is a coordinated roadmap that identifies every piece of evidence a product will need — from clinical trial data to real-world evidence (RWE) to health economic modeling — and aligns it across functions so the same underlying data can serve multiple audiences. Rather than clinical, medical affairs, and market access teams independently commissioning overlapping studies, an IEP forces early, shared visibility into evidence gaps and dependencies. Done well, it reduces duplicated spend and shortens the time between data generation and its use in a regulatory submission, payer negotiation, or physician conversation.

Why This Has Become a Priority

A few forces have pushed integrated evidence planning from a nice-to-have to a near-necessity. Payers increasingly demand real-world evidence alongside clinical trial data before agreeing to reimbursement. Regulatory bodies are more open to non-traditional evidence sources, including RWE, in certain approval pathways. And the cost of generating evidence — running trials, conducting outcomes studies — keeps climbing, making duplicated or poorly sequenced evidence generation an expensive mistake. Building the plan early, ideally starting in early clinical development rather than post-approval, gives teams room to design studies that serve multiple purposes from the outset.

How Digital Transformation Is Reshaping Evidence Planning

Life sciences digital transformation touches nearly every function, but its effect on evidence planning is particularly direct in a few areas:

Unified Data Infrastructure

Historically, clinical, HEOR, and medical affairs teams often worked from separate data systems with limited visibility into each other's evidence. Modern data platforms increasingly bring these sources together, giving teams a shared view of what evidence already exists and what gaps remain — a prerequisite for genuine integration rather than integration in name only.

Real-World Evidence at Scale

The growth of electronic health records, claims data, and patient registries has made real-world evidence far more accessible than it was a decade ago. Digital tools now allow teams to query these sources more efficiently, shortening the time between identifying an evidence gap and generating data to fill it.

AI-Assisted Evidence Synthesis

Emerging tools can help teams synthesize existing literature, flag evidence gaps against a product's competitive landscape, and even model expected payer or regulatory questions before they arise — compressing planning cycles that used to take months of manual literature review.

Cross-Functional Collaboration Platforms

Because an IEP is inherently cross-functional, digital collaboration tools that let clinical, HEOR, medical affairs, and market access teams work from a single, continuously updated plan — rather than static slide decks refreshed once a year — have become central to keeping evidence plans genuinely "living" documents rather than one-time exercises.

Building an Integrated Evidence Plan: A Practical Starting Point

Organizations building or refreshing an IEP typically work through a few core steps:

1. Map the evidence landscape. Catalog what evidence already exists across functions and where genuine gaps remain.

2. Identify stakeholder evidence needs. Regulators, payers, physicians, and patients each need different types of evidence — map these explicitly rather than assuming one dataset serves everyone.

3. Prioritize and sequence. Not every evidence gap can be addressed simultaneously; sequence based on near-term regulatory or commercial milestones.

4. Build in continuous review. An IEP built once and shelved loses value quickly as new data, competitor moves, or regulatory shifts emerge — treat it as a living plan with scheduled updates.

Common Challenges

Even well-resourced organizations run into recurring obstacles: functional silos that resist genuinely shared planning, data systems that don't talk to each other despite investment in digital tools, and a tendency to treat the IEP as a one-time deliverable rather than an ongoing process. Overcoming these usually requires executive sponsorship that spans functions, not just a single team owning the initiative.

Measuring Whether an Integrated Evidence Plan Is Working

Because an IEP touches so many functions, it's worth defining upfront what "working" looks like. Useful indicators include how often evidence generated for one purpose ends up being reused elsewhere without a separate study, how much lead time exists between identifying a gap and having data to address it, and whether cross-functional teams actually consult the plan when making decisions or let it sit unused after the initial planning exercise. Organizations that track these signals catch a stalling IEP early, before it quietly reverts to siloed, function-by-function evidence generation.

The Organizational Side of Digital Transformation

Technology alone doesn't produce integration — tools have to be paired with changes in how teams work together. Companies that see the most benefit typically pair new platforms with structural changes: a named evidence strategy lead who sits above any single function, recurring cross-functional review meetings built into the development calendar, and shared metrics rather than each function optimizing for its own evidence needs in isolation. Change management matters here too — teams accustomed to owning their own evidence process can be reluctant to cede visibility, particularly if incentives haven't been updated to reward cross-functional collaboration. Addressing this typically requires explicit executive sponsorship and a genuine cultural shift toward treating evidence as a shared asset.

Integrated evidence planning and digital transformation are increasingly two sides of the same effort: better technology makes true cross-functional integration achievable, and the discipline of integrated planning gives digital investment a clear, high-value use case rather than technology adoption for its own sake.

FAQs / Q&A

Q1. What's the difference between an integrated evidence plan and a standard clinical development plan? A clinical development plan focuses primarily on the trials needed for regulatory approval. An integrated evidence plan is broader, coordinating clinical, real-world, and health economic evidence across regulatory, payer, and physician audiences throughout the product's full lifecycle.

Q2. When should a company start building its integrated evidence plan? Ideally during early clinical development, well before regulatory submission. Starting early allows trial design to account for evidence needs beyond regulatory approval, such as data payers or physicians will later require.

Q3. Who typically owns the integrated evidence planning process? It varies by organization, but it usually requires shared ownership across medical affairs, HEOR, clinical development, and market access, often coordinated by a dedicated evidence strategy or medical affairs lead rather than sitting entirely within one function.

Q4. How does real-world evidence fit into an integrated evidence plan? RWE increasingly supplements clinical trial data, particularly for demonstrating long-term safety, effectiveness in broader populations, or value for payer negotiations — areas where traditional randomized trials are limited or impractical.

Q5. What role does digital transformation play in evidence planning specifically? It primarily improves access to and synthesis of evidence — through unified data platforms, more accessible real-world data sources, and tools that help teams identify evidence gaps faster than manual, function-by-function review.

ZS is a management consulting and technology firm focused on transforming global healthcare and beyond. We leverage leading-edge analytics, data and science to help clients make intelligent decisions.